PTC Therapeutics Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.69 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $64.13Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $5.4B Enterprise Value $4.9B Shares Outstanding 93.6M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary PTC Therapeutics is successfully transitioning from a legacy rare disease business to a high-growth commercial model, anchored by the outstanding global launch of Sephience (sepiapterin) for phenylketonuria (PKU). The company's Q1 2026 results demonstrated robust operational execution, leading management to raise full-year product revenue guidance. While the capital structure remains leveraged with significant royalty obligations, the recent refinancing of its 2026 convertible notes into zero-coupon 2031 notes significantly improves near-term liquidity and reduces cash interest expenses. With multiple late-stage pipeline catalysts under FDA review, PTC is well-positioned to unlock substantial shareholder value. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$70.00 Mean target$99.29 High · most bullish analyst$130.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $70.00 Sephience growth slows down due to reimbursement hurdles or competitive pressures. Regulatory setbacks occur for key pipeline candidates (e.g., FDA rejection or delays for vatiquinone or Translarna), leaving the company heavily reliant on its existing portfolio while managing its substantial royalty liabilities. Base CaseCentral scenario $99.29 Matches the consensus meanSephience maintains its strong launch trajectory in the US and successfully rolls out internationally, meeting raised full-year product revenue guidance of $750M-$850M. Pipeline assets progress steadily, and the company continues to optimize its capital structure following the successful $550M zero-coupon convertible note offering. Bull CaseUpside scenario $130.00 Sephience global adoption accelerates faster than expected, surpassing the high end of guidance. FDA grants approval for both vatiquinone (Friedreich's ataxia) and Translarna, driving a massive expansion of the commercial portfolio and establishing PTC as a diversified rare disease powerhouse with multiple blockbusters. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |